Cargando…

Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease

OBJECTIVES: Little is known about erythropoiesis-stimulating agents (ESAs) utilization among lupus nephritis (LN) patients with incipient ESRD. We aimed to identify sociodemographic and clinical factors associated with ESA use among incident LN ESRD patients. METHODS: Among all individuals age ≥18 w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gómez-Puerta, José A, Waikar, Sushrut S, Solomon, Daniel H, Liu, Jun, Alarcón, Graciela S, Winkelmayer, Wolfgang C, Costenbader, Karen H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963515/ https://www.ncbi.nlm.nih.gov/pubmed/24672742 http://dx.doi.org/10.4172/2155-9899.1000179

Ejemplares similares

Renal deposits of complement factors as predictors of end-stage renal disease and death in patients with lupus nephritis
por: Koopman, Jacob J E, et al.
Publicado: (2020)

Prevalence and demographics of systemic lupus erythematosus and lupus nephritis among US children with Medicaid coverage, 2002-2004
por: Hiraki, Linda T, et al.
Publicado: (2012)

Variation in renal biopsy and medication prescribing practices among pediatric Medicaid patients with lupus nephritis prior to end-stage renal disease in the US, 2000 to 2004
por: Hiraki, LT, et al.
Publicado: (2012)

Sociodemographics and epidemiology of serious infections requiring hospitalization among adults with systemic lupus erythematosus and lupus nephritis, 2000 to 2006
por: Feldman, Candace H, et al.
Publicado: (2014)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

Serious infection incidence rates in pediatric systemic lupus erythematosus according to medication use
por: Hiraki, Linda T, et al.
Publicado: (2014)

Erythropoiesis stimulating agents: approaches to modulate activity
por: Sinclair, Angus M
Publicado: (2013)

Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent
por: Heldeweg, Micah L. A., et al.
Publicado: (2023)

Effect of roxadustat on serum metabolome and lipidome in patients with end-stage renal disease and erythropoiesis-stimulating agent resistance
por: Wang, Lichao, et al.
Publicado: (2022)

Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection
por: Shah, Hitesh H., et al.
Publicado: (2020)

Erythropoiesis‐stimulating agents and incident malignancy in chronic kidney and end‐stage renal disease: A population‐based study
por: Huang, Yu‐Shan, et al.
Publicado: (2022)

Dialysis and Pregnancy in End Stage Kidney Disease Associated with Lupus Nephritis
por: Sivasuthan, Goutham, et al.
Publicado: (2013)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19
por: Fishbane, Steven, et al.
Publicado: (2020)

Mechanisms of hemoglobin cycling in anemia patients treated with erythropoiesis-stimulating agents
por: Jörg, David J., et al.
Publicado: (2023)

Lupus Nephritis With Collapsing Glomerulopathy: A Rare Association
por: Dubey, Shubham, et al.
Publicado: (2023)

Methodological quality of studies of end-stage renal disease risks in lupus nephritis
por: Tektonidou, Maria, et al.
Publicado: (2014)

Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
por: Melosky, B.L.
Publicado: (2008)

Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents
por: Yan, X, et al.
Publicado: (2013)

Erythropoiesis stimulating agents and reno-protection: a meta-analysis
por: Elliott, Steve, et al.
Publicado: (2017)

Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?
por: Wish, Jay B.
Publicado: (2020)

Selenium Associates With Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Yasukawa, Minoru, et al.
Publicado: (2022)

Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Lee, Yu-Ting, et al.
Publicado: (2022)

End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia
por: Hoque, Shamia, et al.
Publicado: (2020)

Granulocyte colony‐stimulating factor is not pathogenic in lupus nephritis
por: Gottschalk, Timothy A., et al.
Publicado: (2021)

Metastatic pulmonary calcification on bone scintigraphy of a patient with lupus nephritis and end-stage renal disease
por: Cheng, Nina H., et al.
Publicado: (2023)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2016)

Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients
por: Anker, Stefan D., et al.
Publicado: (2009)

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
por: Aapro, M, et al.
Publicado: (2012)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia
por: Pashos, Chris L., et al.
Publicado: (2011)

Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
por: Suttorp, Marit M, et al.
Publicado: (2013)

Effect of Erythropoiesis-Stimulating Agents on Blood Pressure in Pre-Dialysis Patients
por: Suttorp, Marit M., et al.
Publicado: (2013)

Neuroimaging in Former Preterm Children Who Received Erythropoiesis Stimulating Agents
por: Phillips, Authors: John, et al.
Publicado: (2017)

Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality
por: Karaboyas, Angelo, et al.
Publicado: (2020)

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes
por: Hattakitpanitchakul, Saroj, et al.
Publicado: (2021)

A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders
por: Das, Monojit, et al.
Publicado: (2022)

Usual source of care and geographic region are largest predictors of healthcare quality for incident lupus nephritis in US Medicaid recipients
por: Yazdany, J, et al.
Publicado: (2012)

Contemporary estimates of the risk of end-stage renal disease in the first decade of proliferative lupus nephritis
por: Ward, MM, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_erc599jtam48q88av46ntm6tms